Albumin lymphocyte index is a better predictor of overall survival than neutrophil lymphocyte ratio in bladder cancer patients treated by radical radiotherapy

Background/Aims: Emerging studies have shown that the neutrophil-lymphocyte ratio (NLR) is a potential predictor in various tumors. Our study was conducted to assess the prognostic value of the pretreatment NLR in bladder cancer and metastatic or unresectable urothelial carcinoma (mUC or uUC) patients up to July 2017. The correlation between the pretreatment NLR and pathological characteristics was also evaluated in bladder cancer patients. Methods: The hazard ratio (HR) and odds ratio (OR) with the 95% confidence interval (CI) were extracted or calculated from the included studies for further pooled analysis. A total of 21 studies were included in a pooled analysis. Results: The pooled results indicated that a high pretreatment NLR was associated with reduced overall survival (OS) (HR=1.27, 95% CI=1.12-1.43), relapse-free survival (RFS) (HR=1.41, 95% CI=1.23-1.60), progression-free survival (PFS) (HR=1.75, 95% CI=1.36-2.15), disease-specific survival (DSS) and cancer-specific survival (CSS) (HR=1.27, 95% CI=1.19-1.35) in the bladder cancer patients. Additionally, an elevated pretreatment NLR suggested a worse OS rate in the mUC or uUC patients (HR=1.63, 95% CI=1.34-1.91). The pooled ORs and 95% CIs showed that a high pretreatment NLR could be a risk indicator for certain pathological features, such as lymphovascular invasion, a positive margin status and advanced tumor stage. Conclusions: our results showed that a high pretreatment NLR predicted poor prognosis in bladder cancer, mUC and uUC patients.

Download Full-text

Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors for locally advanced pancreatic cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.4_suppl.326 ◽

2017 ◽

Vol 35 (4_suppl) ◽

pp. 326-326

Author(s):

Byung Min Lee ◽

Seung Yeun Chung ◽

Jee Suk Chang ◽

Kyong Joo Lee ◽

Si Young Song ◽

...

Keyword(s):

Pancreatic Cancer ◽

Overall Survival ◽

Prognostic Factors ◽

Cancer Patients ◽

Locally Advanced ◽

Advanced Pancreatic Cancer ◽

Locally Advanced Pancreatic Cancer ◽

Neutrophil Lymphocyte Ratio ◽

Lymphocyte Ratio ◽

Pre Treatment

326 Background: It is well known that locally advanced pancreatic cancer patients have a poor prognosis. Recently, hematologic markers showing systemic inflammatory status such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have aroused much attention due to its potential to predict patient survival. In this study, we investigated whether pre-treatment NLR and PLR independently and in combination would be significant prognostic factors for survival in locally advanced pancreatic cancer patients. Methods: A total of 497 locally advanced (borderline resectable and unresectable) pancreatic cancer patients who received neoadjuvant or definitive chemoradiotherapy (CCRT) between January 2005 and December 2015 were included in this study. NLR and PLR prior to the start of treatment within 2 weeks were defined as pre-treatment NLR and PLR. We divided the patients with the median values of pre-treatment NLR and PLR; NLR < 2.44 group (n = 248), NLR ≥ 2.44 group (n = 249), PLR < 149 group (n = 248) and PLR ≥ 149 (n = 249) group. Overall survival (OS) and progression-free survival (PFS) were compared between each group for NLR and PLR. Results: Median overall survival was 15.7 months (range, 2.3-128.5 months). For NLR, the OS, PFS rates were significantly lower in the NLR ≥ 2.44 group, with 1-year OS rates of 67.9% and 61.5% (p = 0.003) and 1-year PFS rates of 38.1% and 32.4% (p = 0.003), for NLR < 2.44 and ≥ 2.44 group, respectively. The PLR ≥ 149 group also showed significantly poorer OS and PFS than PLR < 149 group. The 1-year OS rates were 68.1% and 61.3% (p = 0.029) and 1-year PFS rates were 37.9% and 32.5% (p = 0.027), for PLR < 149 and ≥ 149 group, respectively. When multivariate analysis was performed, NLR ≥ 2.44 remained as a significant adverse factor for OS (p = 0.011) and PFS (p = 0.026). PLR > 149 also proved to be a significant factor for poorer OS (p = 0.003) and PFS (p = 0.021). Conclusions: Elevated pre-treatment NLR and PLR independently and in combination significantly predicted poor OS and PFS. Pre-treatment NLR and PLR are useful prognostic factors for OS and PFS in locally advanced pancreatic cancer patients.

Download Full-text

The prognostic role of preoperative circulating neutrophil–lymphocyte ratio in primary bladder cancer patients undergoing radical cystectomy: a meta-analysis

World Journal of Urology ◽

10.1007/s00345-018-2593-z ◽

2018 ◽

Vol 37 (9) ◽

pp. 1817-1825 ◽

Cited By ~ 6

Author(s):

Guoming Hu ◽

Feng Xu ◽

Kefang Zhong ◽

Shimin Wang ◽

Qi Xu ◽

...

Keyword(s):

Bladder Cancer ◽

Cancer Patients ◽

Radical Cystectomy ◽

Meta Analysis ◽

Prognostic Role ◽

Neutrophil Lymphocyte Ratio ◽

Lymphocyte Ratio ◽

Primary Bladder ◽

Primary Bladder Cancer

Download Full-text

Perioperative change in neutrophil–lymphocyte ratio predicts the overall survival of patients with bladder cancer undergoing radical cystectomy

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyw129 ◽

2016 ◽

Vol 46 (12) ◽

pp. 1162-1167 ◽

Cited By ~ 7

Author(s):

Takashi Yoshida ◽

Hidefumi Kinoshita ◽

Kenji Yoshida ◽

Takao Mishima ◽

Masaaki Yanishi ◽

...

Keyword(s):

Overall Survival ◽

Bladder Cancer ◽

Radical Cystectomy ◽

Neutrophil Lymphocyte Ratio ◽

Lymphocyte Ratio

Download Full-text

Preoperative fibrinogen-to-prealbumin ratio and neutrophil lymphocyte ratio/prealbumin ratio versus platelet distribution width-to-platelet count ratio as a prognostic predictor for bladder cancer

10.21203/rs.3.rs-721551/v1 ◽

2021 ◽

Author(s):

jiacheng wu ◽

Baoqian Zhai ◽

Tao Li ◽

Xiaolin Wang

Keyword(s):

Bladder Cancer ◽

Multivariate Analysis ◽

Platelet Count ◽

Cancer Patients ◽

Platelet Distribution Width ◽

Distribution Width ◽

Cox Regression Analysis ◽

Neutrophil Lymphocyte Ratio ◽

Lymphocyte Ratio ◽

Count Ratio

Abstract Background Evidence indicates that preoperative fibrinogen/prealbumin (FPR), neutrophil lymphocyte ratio/prealbumin ratio (NLR/PA) and platelet distribution width-to-platelet count ratio (PDW/PLT) possess prognostic potential in numerous malignancies. However, their roles in bladder cancer remain unclear. In this study, we investigated the association between FPR, NLR/PA versus PDW/PLT and the prognosis in bladder cancer patients. Methods The clinical data of 147 patients with bladder cancer treated in Nantong cancer hospital from January 2009 to August 2014 were retrospectively analyzed. According to ROC curve, the optimal critical value of FPR, NLR/PA and PDW/PLT were 0.1084, 0.1045 and 0.1210 respectively. The patients were followed up for 5 years to observe the survival of the patients, and the clinicopathological data were statistically analyzed. Cox regression analysis was used for univariate and multivariate analysis. Finally, on this basis, the nomogram is constructed for internal verification. Results All patients were followed up for 5 years. A total of 102 patients survived with a survival rate of 69.4%, 45 patients died with a mortality rate of 30.6%. Further stratified analysis showed that the group with low FPR, low NLR/PA and low PDW/PLT had the best prognosis, while the group with high FPR, high NLR/PA and high PDW/PLT had the worst prognosis. Cox multivariate analysis showed that preoperative FPR, NLR/PA and PDW/PLT were independent risk factors for tumor progression (p = 0.007, p = 0.013, p = 0.000). The decrease of FPR, NLR/PA and PDW/PLT can significantly prolong OS and PFS in patients with bladder cancer. In internal validation, the c-index of the nomogram was 0.8140 (95% CI: 0.7577–0.8703). Conclusions Preoperative FPR and NLR/PA versus PDW/PLT can be an independent prognostic factor in bladder cancer patients and are associated with clinicopathological characteristics. They have a specific value in assessing the prognosis of bladder cancer patients.

Download Full-text

The values of several inflammatory markers, including the neutrophil/lymphocyte ratio, in patients with pancreatic cancer treated by curative resection followed by adjuvant chemotherapy

International Surgery ◽

10.9738/intsurg-d-16-00129.1 ◽

2017 ◽

Author(s):

Yusuke Nakayama ◽

Naoto Gotohda ◽

Shinichiro Takahashi ◽

Masaru Konishi ◽

Ryuichi Hayashi

Keyword(s):

Pancreatic Cancer ◽

Overall Survival ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Inflammatory Markers ◽

Curative Resection ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Neutrophil Lymphocyte Ratio ◽

Lymphocyte Ratio

Abstract Objective: The aim of this study was to determine the relationship between the values of several systemic inflammatory markers and the prognosis in pancreatic cancer patients treated by curative resection followed by adjuvant chemotherapy. Methods: A total of 110 pancreatic cancer patients who treated by curative resection followed by adjuvant chemotherapy were reviewed for this study. Univariate and multivariate analyses were performed to identify the clinicopathological factors influencing the overall survival, including the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), Glasgow prognostic score (GPS), and the direction of change of the NLR (increase or decrease) after one cycle of adjuvant chemotherapy as compared to the value recorded prior to the start of the chemotherapy. Results: A multivariate analysis identified only the direction of change of the NLR after the first cycle of adjuvant chemotherapy as an independent risk factor for the overall survival (NLR decrease vs. NLR increase, HR=1.925; P=0.044). The NLR, PLR and GPS were not identified as significant predictors of the overall survival. Conclusions: The direction of change of the NLR after the first cycle of adjuvant chemotherapy may help in predicting the effect of chemotherapy in pancreatic cancer patients treated by curative resection followed by adjuvant chemotherapy.

Download Full-text

Abstract P4-11-41: Pretreatment neutrophil/lymphocyte ratio and overall survival in African American and white breast cancer patients

10.1158/1538-7445.sabcs14-p4-11-41 ◽

2015 ◽

Author(s):

Joseph C Rimando ◽

Jeff Campbell ◽

Jae Hee Kim ◽

Sangmi Kim

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

African American ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Neutrophil Lymphocyte Ratio ◽

Lymphocyte Ratio

Download Full-text

Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy

Scientific Reports ◽

10.1038/s41598-021-86019-2 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Yu-Chieh Ho ◽

Yuan-Chun Lai ◽

Hsuan-Yu Lin ◽

Ming-Hui Ko ◽

Sheng-Hung Wang ◽

...

Keyword(s):

Overall Survival ◽

Cancer Patients ◽

Squamous Cell ◽

Squamous Cell Cancer ◽

Performance Status ◽

Cell Cancer ◽

Esophageal Squamous Cell Cancer ◽

Lymphocyte Ratio ◽

Cardiac Dose

AbstractWe aimed to determine the prognostic significance of cardiac dose and hematological immunity parameters in esophageal cancer patients after concurrent chemoradiotherapy (CCRT). During 2010–2015, we identified 101 newly diagnosed esophageal squamous cell cancer patients who had completed definitive CCRT. Patients' clinical, dosimetric, and hematological data, including absolute neutrophil count, absolute lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR), at baseline, during, and post-CCRT were analyzed. Cox proportional hazards were calculated to identify potential risk factors for overall survival (OS). Median OS was 13 months (95% confidence interval [CI]: 10.38–15.63). Univariate analysis revealed that male sex, poor performance status, advanced nodal stage, higher percentage of heart receiving 10 Gy (heart V10), and higher NLR (baseline and follow-up) were significantly associated with worse OS. In multivariate analysis, performance status (ECOG 0 & 1 vs. 2; hazard ratio [HR] 3.12, 95% CI 1.30–7.48), heart V10 (> 84% vs. ≤ 84%; HR 2.24, 95% CI 1.26–3.95), baseline NLR (> 3.56 vs. ≤ 3.56; HR 2.36, 95% CI 1.39–4.00), and follow-up NLR (> 7.4 vs. ≤ 7.4; HR 1.95, 95% CI 1.12–3.41) correlated with worse OS. Volume of low cardiac dose and NLR (baseline and follow-up) were associated with worse patient survival.

Download Full-text

The role of neutrophil-lymphocyte ratio as a prognostic indicator in patients undergoing nephrectomy for renal cell carcinoma

Canadian Urological Association Journal ◽

10.5489/cuaj.4872 ◽

2018 ◽

Vol 12 (7) ◽

pp. E348-8 ◽

Cited By ~ 5

Author(s):

Nathan Grimes ◽

Cathal Hannan ◽

Matthew Tyson ◽

Ali Thwaini

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Renal Cell ◽

Primary Tumour ◽

Preoperative Staging ◽

Recurrence Free Survival ◽

Free Survival ◽

Neutrophil Lymphocyte Ratio ◽

Lymphocyte Ratio

Introduction: Prognosis in patients with cancer is influenced by underlying tumour biology and also the host inflammatory response to the disease. There is limited evidence to suggest that an elevated neutrophil-lymphocyte ratio (NLR) predicts a poorer prognosis in patients undergoing nephrectomy for renal cell carcinoma (RCC). The aim of this paper is to investigate if patients undergoing nephrectomy for RCC with NLR ≤4 have a better overall and recurrence-free survival than patients with NLR >4.Methods: All patients who underwent nephrectomy at a single centre between January 1, 2011 and December 31, 2014 were identified. Patients were included if postoperative histology demonstrated RCC and if preoperative NLR was available. Patients were excluded if nephrectomy was not curative intent (i.e., cytoreductive nephrectomy), if primary tumour was graded to be T3b‒4 disease, if there was presence of nodal or metastatic disease on preoperative staging, or if adequate followup notes were not available. Primary and secondary outcomes were overall survival and recurrence-free survival, respectively.Results: A total of 154 patients were included in analysis of overall survival; 146 patients were included in analysis of recurrence-free survival. Patients with NLR ≤4 had a much better overall survival than patients with NLR >4 (95% vs. 78%; p=0.0219). Patients with NLR >4 also had higher rates of recurrence (p=0.0218).Conclusions: NLR may be a useful tool in identifying patients who may benefit from more frequent surveillance in the early postoperative period and may allow clinicians to offer surveillance schemes tailored to the individual patient.

Download Full-text